Oxford Centre for Haematology
The OCH Management Board has as members the Director of the OCH, the Head of Clinical Haematology, the Head of Laboratory Haematology, the Head of the Radcliffe Department of Medicine, the Head of the Nuffield Division of Clinical Laboratory Sciences, the Director of the MRC Molecular Haematology Unit, the Director of the MRC Human Immunology Unit, the RDM Research Strategy Coordinator and the Administrator of the OCH.
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C. et al, (2021), J Exp Med, 218
Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial.
Law ZK. et al, (2021), J Am Heart Assoc
To Bi or not to Bi: Acute Erythroid Leukemias and hematopoietic lineage choice.
di Genua C. and Nerlov C., (2021), Exp Hematol
COVID-19 convalescent plasma: interim recommendations from the AABB.
Cohn CS. et al, (2021), Transfusion
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Estcourt L., (2021), New England Journal of Medicine
21 August 2020
MRC WIMM researchers have developed a new method to quickly identify cancerous cells in babies at risk of leukaemia. The team hope that the new protocol could make rapid testing more accessible for clinical laboratories around the globe.
26 May 2020
The collaboration has led to the first pre-clinical model of acute erythroid leukaemia.
21 January 2020
Congratulations to Dr Simona Valletta and Dr Sarah Gooding, who were selected for the Translational Research Training in Hematology Program, a year-long training and mentoring experience by the American Society of Hematology and the European Hematology Association.
28 June 2021: Oxford Centre for Haematology Annual Meeting
Please email for further information